Vertex Pharmaceuticals
NASDAQ: VRTX
Vertex Pharmaceuticals is a biotechnology company that develops and commercializes medicines for serious diseases. Its core business focuses on cystic fibrosis treatments, with additional products for sickle cell disease, beta thalassemia and acute pain. Its expanding portfolio and drug development pipeline are key areas analysts evaluate.
- Sektor
- Health Technology
- Industri
- Pharmaceuticals: Major
- Pekerja
- 6,400
- Ditubuhkan
- 1989
- Laman web
- vrtx.com ↗
Angka ramalan ini milik tipranks, dibaca pada 2026-10-26 dan dipautkan di bawah.
Maklumat syarikat dan kewangan milik CNN Business, dibaca pada 2026-11-16 dan dipautkan di bawah.
Ramalan Vertex Pharmaceuticals
Ringkasan ramalan
tipranks merekodkan 24 penarafan penganalisis bagi Vertex Pharmaceuticals dan merumuskannya sebagai “Strong Buy”. Harga sasaran purata 12 bulan mereka ialah USD 589.45 (Potential Growth = 12.51%). Skor tipranks baginya ialah 8 daripada 10 — Outperform. Ini angka tipranks seperti yang dibaca pada 2026-10-26, bukan pandangan CariBroker sendiri, dan tiada apa-apa di sini merupakan nasihat untuk membeli atau menjual.
Permodalan pasaran
USD 136.01 B
≈ RM 556.36 B
Harga saham
USD 536.45
≈ RM 2194.40 · 18 Nov close
#163Kedudukan dunia
Skor tipranks
Outperform
Penarafan penganalisis
Strong Buy
- Beli2188%
- Pegang313%
- Jual00%
Rumusan tipranks sendiri bagi 24 penarafan di atas.
Ramalan harga 12 bulan
USD 589.45 Potential Growth = 12.51%
Seperti yang diterbitkan tipranks. CariBroker tidak mengira semula apa-apa.
Kewangan
Q3 earnings, quarter ending Sep 29, 2026
| Ukuran | Q3 2026 | Perubahan 1 tahun |
|---|---|---|
| Jumlah hasil | 3.44B | 6.57% up |
| Pendapatan bersih | 653.60M | 45.13% down |
| Perolehan sesaham | 2.56 | 39.08% down |
| Margin keuntungan bersih | 19.01% | 45.32% down |
| Aliran tunai bebas | 545.80M | 56.57% up |
| Nisbah hutang kepada ekuiti | 0.31 | 192.48% up |
Hasil dan pendapatan bersih, 4 suku terakhir
Jumlah hasilPendapatan bersih
Profil penganalisis: siapa membuat setiap panggilan, dan bila
| Penganalisis | Daripada | Kedudukan | Harga sasaran | Bertarikh |
|---|---|---|---|---|
| Michael Yee | UBS | Buy | USD 615 | 2026-10-24 |
| Geoff Meacham | Citi | Buy | USD 585 | 2026-10-19 |
| Tazeen Ahmad | Bank of America Securities | Buy | USD 667 | 2026-10-16 |
| Mohit Bansal | Wells Fargo | Buy | USD 550 | 2026-10-15 |
| Evan Seigerman | BMO Capital | Buy | USD 600 | 2026-10-12 |
Tunjuk kesemua 30
| Penganalisis | Daripada | Kedudukan | Harga sasaran | Bertarikh |
|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Buy | USD 576 | 2026-10-08 |
| Terence Flynn | Morgan Stanley | Buy | USD 665 | 2026-10-07 |
| Jeffrey Walch | Bernstein | Buy | USD 608 | 2026-09-25 |
| Eliana Merle | Barclays | Buy | USD 617 | 2026-09-23 |
| Danielle Brill | Truist Financial | Buy | N/A | 2026-09-23 |
| Whitney Ijem | Canaccord Genuity | Hold | USD 442 | 2026-09-23 |
| Louise Chen | Scotiabank | Buy | USD 558 | 2026-09-23 |
| Akash Tewari | Jefferies | Buy | USD 640 | 2026-09-23 |
| Paul Matteis | Stifel Nicolaus | Hold | N/A | 2026-09-22 |
| Salveen Richter | Goldman Sachs | Buy | USD 653 | 2026-09-22 |
| Andrew Fein | H.C. Wainwright | Buy | USD 641 | 2026-09-22 |
| Myles Minter | William Blair | Buy | N/A | 2026-09-22 |
| Jessica Fye | J.P. Morgan | Buy | USD 560 | 2026-09-11 |
| Naz Rahman | Maxim Group | Buy | USD 575 | 2026-08-05 |
| Phil Nadeau | TD Cowen | Buy | USD 550 | 2026-08-04 |
| Carter Gould | Cantor Fitzgerald | Buy | USD 595 | 2026-08-04 |
| Joseph Stringer | Needham | Hold | N/A | 2026-08-04 |
| Cory Kasimov | Evercore ISI | Buy | USD 535 | 2026-08-04 |
| Andy Chen | Wolfe Research | Buy | USD 557 | 2026-08-03 |
| Brian Skorney | Robert W. Baird | Sell | USD 350 | 2026-07-07 |
| Unknown Analyst | Raymond James | Hold | N/A | 2026-06-24 |
| Unknown Analyst | Guggenheim | Buy | USD 546 | 2026-06-02 |
| Hans Engel | Erste Group | Hold | N/A | 2026-05-05 |
| Nico Chen | DBS | Buy | USD 540 | 2026-01-19 |
| David Risinger | Leerink Partners | Buy | USD 525 | 2025-12-29 |
Kekuatan pelaburan
High-quality profitability and cash generation
Vertex combines substantial revenue with unusually strong margins and cash conversion, giving it internal funding capacity for research, launches and business development. This financial strength can support investment through development cycles while reducing reliance on external financing over the next several quarters.
Durable cystic fibrosis franchise growth
The CF franchise continues to expand through uptake of ALYFTREK, supporting recurring demand from patients using chronic therapies. Growth in the established franchise provides a durable commercial base and creates resources to fund Vertex’s newer launches and pipeline programs.
Pipeline diversification and launch execution
Progress across cell therapy, pain, renal disease and other clinical programs reduces reliance on a single future product while broadening Vertex’s potential commercial base. Continued launches and advancing studies create multiple avenues for growth beyond its historical CF concentration.
Soalan lazim
Berapakah harga sasaran 12 bulan bagi Vertex Pharmaceuticals (VRTX)?
tipranks menerbitkan harga sasaran purata 12 bulan sebanyak USD 589.45 (Potential Growth = 12.51%), seperti yang dibaca pada 2026-10-26. Sasaran tertinggi ialah USD 667 dan yang terendah ialah USD 442. Harga sasaran ialah anggaran penganalisis tentang harga saham, bukan janji, dan CariBroker tidak memberikan nasihat pelaburan.
Berapa ramai penganalisis melitupi Vertex Pharmaceuticals (VRTX)?
tipranks merekodkan 24 penarafan penganalisis: 21 beli, 3 pegang dan 0 jual, yang dirumuskannya sebagai “Strong Buy”, seperti yang dibaca pada 2026-10-26.
Apakah skor tipranks bagi Vertex Pharmaceuticals (VRTX)?
tipranks memberikannya 8 daripada 10 dan menyebutnya “Outperform”, seperti yang dibaca pada 2026-10-26. Skor itu milik tipranks, bukan CariBroker, dan CariBroker tidak menarafkan saham tersenarai.
Adakah ini ramalan CariBroker sendiri bagi Vertex Pharmaceuticals?
Tidak. Setiap angka di halaman ini diterbitkan oleh tipranks, disalin pada 2026-10-26 dengan pautan ke sumber asalnya, dan tidak dikira semula. CariBroker menyemak syarikat kewangan di Malaysia berdasarkan daftar awam; kami tidak membuat ramalan sendiri dan tidak memegang lesen untuk menasihati tentang sekuriti.
Penafian
CariBroker menyediakan maklumat sahaja dan tidak memberikan nasihat pelaburan, kewangan atau undang-undang.
Semak syarikat lain
Cari semua bank, broker dan senarai amaran di satu tempat
